We set out to identify the prognostic factors in adult patients with Candida spp. bloodstream infection, assessing the impact on in-hospital mortality of catheter removal and adequacy of antifungal therapy.
Introduction
Bloodstream infections (BSIs) due to Candida spp. are a serious complication in hospitalized patients, with a high fatality rate. In addition, patients with candidaemia, compared with patients with BSIs caused by bacterial pathogens, have the greatest mortality rates. 1 More importantly, after controlling for confounders, candidaemia has been identified as an independent predictor of mortality. 2 Therefore, clinicians should strive to achieve prompt and correct management of patients with candidaemia in an attempt to improve this poor outcome. Two interventions are considered the standard of care in candidaemic patients: use of adequate antifungal therapy and catheter removal. However, conflicting data exist regarding the most appropriate time for catheter withdrawal and the population of patients that would benefit most from such intervention. Diverse studies have concluded that, in patients with Candida spp. BSIs, early catheter removal is associated with a reduction in the death risk, 3 while others concluded that the timing of catheter withdrawal does not influence the outcome. 4, 5 These authors identified severity of illness in patients with Candida spp. BSI as the most predictive variable associated with in-hospital mortality. It is noteworthy that the impact on # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 206 -213 doi:10.1093/jac/dks347 Advance Access publication 3 September 2012 mortality of early antifungal therapy was not assessed in these studies that evaluated the timing of catheter removal.
Moreover, the role of early antifungal therapy in patients with candidaemia has also yielded contradictory results. Thus, although many studies have concluded that the timing of antifungal administration is crucial in terms of survival, 6 -10 others have not supported this observation. 11 -14 Similarly, the role of catheter removal has not been taken into account in the majority of these studies. Thus, removal of the catheter in addition to having received at least 5 days of antifungal treatment was independently associated with a lower risk of death at days 8 -30 post-candidaemia. 6 However, the timing of initiating these two therapeutic interventions was not reported.
The objective of the present study was to determine the prognostic factors in adult patients with Candida spp. BSI, assessing specifically the impact on mortality of early catheter removal and adequate antifungal therapy. In addition, we carried out the same analysis in two sub-groups of subjects: patients with primary candidaemia and cases of secondary non-catheterrelated candidaemia.
Methods

Hospital
This was a prospective study carried out in the Hospital Virgen del Rocío from January 2004 to June 2009. This is a large urban Hospital with teaching accreditation. The study was approved by the Ethics Committee of the hospital, which waived the need for written consent, given the observational nature of this research.
Study design
All adult patients (≥18 years) with at least one positive blood culture for Candida spp. identified by the Microbiology Service and with a central venous catheter (CVC) that been in place for at least 24 h at the time of candidaemia diagnosis were included in this study. Patients who died before day 2 after candidaemia diagnosis were excluded from this analysis. Candida BSIs occurring in the same patient during the same hospitalization were counted as only one episode.
The following data were collected upon the confirmation of candidaemia: age, gender, underlying diseases (diabetes mellitus, liver cirrhosis, chronic renal disease, active malignancy and HIV status), intravenous use of illicit drugs, solid organ transplantation and bone marrow transplantation. The presence of these variables between the day of hospital admission and the day of candidaemia was also noted: neutropenia (neutrophil count of 500 cells/mL), administration of corticosteroids for any reason, total parenteral nutrition, placement of tunnelled catheter and renal replacement therapy (haemodialysis or continuous haemofiltration).
The origin of candidaemia was investigated in all patients following current recommendations of good clinical practice, including culture of the catheter tip or of the likely source of infection. Patients were considered as having primary candidaemia if there was no apparent portal of entry or if the infection was probably catheter-related. 4 Catheter-related candidaemia required identification of the same Candida species from the peripheral blood and semi-quantitative tip culture (.15 cfu). Secondary non-catheter-related candidaemia was defined as BSIs that occurred after a potential origin was identified where the same species of Candida was isolated in blood culture and in the suspected source of infection.
The following variables were also noted to assess the prognosis of an episode of candidaemia: severity of illness on the day of candidaemia evaluated by APACHE (Acute Physiology and Chronic Health Evaluation) II score, 15 clinical presentation (sepsis, severe sepsis or septic shock), delay of catheter withdrawal and adequacy of empirical therapy. Early CVC removal was defined as removal of the line within the first 48 h following the date of the incident Candida BSI. 4 In patients with multiple CVCs, removal of all catheters within this timeframe was required. Adequate antifungal therapy was also defined as the initiation within 48 h after obtaining the positive blood culture of an intravenous antifungal agent to which the isolated organism was found to be susceptible on the basis of in vitro study and with the correct dose. Initial adequate dosing of fluconazole was defined as 6 mg/kg/day (adjusted for renal function) except for Candida glabrata, which required 12 mg/kg/ day. The dose of caspofungin, the echinocandin on formulary at the time of the study, was a loading dose of 70 mg followed by 50 mg/day adjusted for hepatic function. In the case of liposomal amphotericin B, the adequate dose was at least 3 mg/kg/day.
Candida spp. were isolated from blood using the BACTEC 860 system (Becton Dickinson, Sparks, MD, USA) and were identified using the API-32C system (bioMérieux Vitek, St Louis, MO, USA). Susceptibility to antifungals was measured using Sensititre YeastOne (TREK Diagnostic Systems, East Grinstead, UK). Susceptibility testing, reading and interpretation of the results were performed in accordance with the manufacturer's instructions. The interpretive breakpoints were those proposed in the CLSI (formerly the NCCLS) M44-A reference method.
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Statistical methods
We expressed continuous variables as median and IQR because their distributions were not adjusted on normal distribution. We compared non-normally distributed continuous variables with the Mann-Whitney U-test. Bivariate associations for proportions were performed using the x 2 test or Fisher's exact test as appropriate.
To determine the independent effects of the variables on survival, we calculated the corresponding unadjusted and multivariate-adjusted hazard ratio of death using Cox proportional hazard regression analysis. All covariates with P,0.1 in the unadjusted model, the two therapeutic interventions and their interactions were entered into the multivariate model. Collinearity was assessed via correlation matrixes. Adjusted hazard ratios (aHRs) and their 95% CIs were calculated for each variable. This analysis was performed in the entire cohort, in patients with primary candidaemia (including catheter-related infections) and in secondary non-catheter-related candidaemia.
Statistical significance was defined as P, 0.05. Data were analysed using the statistical software PASW Statistics v 18.0 (Chicago, IL, USA). All reported P values were based on two-tailed tests.
Results
During the study period, 229 episodes of candidaemia were identified. Three patients died on day 0 or 1 and were excluded from the outcome analysis, as were 38 patients without CVC at the moment of candidaemia. Thus, 188 patients were finally evaluable. Median time from hospital admission to candidaemia presentation was 23.5 days (13, 36.5) (p25, p75). Candida albicans was the predominant species (87 patients, 46.3%) followed by C. parapsilosis (37, 19.7%) and C. tropicalis (30, 16.0%). Nonalbicans Candida accounted for 101 (53.7%) of the fungal isolates and 31 (16.5%) of the cases were caused by potentially fluconazole-resistant organisms (C. glabrata or Candida krusei).
The majority of cases were episodes of primary candidaemia (n¼ 148, 78.7%); 66 (35.1%) of them had no apparent portal of entry and 82 (43.6%) were probably catheter-related. Distribution of species was similar in probably catheter-related Candida spp. BSI and in the remaining primary candidaemia episodes. Forty Prognostic factors of Candida spp. bloodstream infections 207 JAC episodes (21.3%) were classified as secondary non-catheterrelated candidaemia. In these cases, the source of infection was abdominal (n¼ 24), urological (n¼ 9) and others (n¼ 7).
Sixty-seven patients (35.6%) died during hospitalization. At the time of candidaemia, 93 (49.5%) patients were in the intensive care unit (ICU). Median time elapsed from ICU admission to the day of candidaemia diagnosis was 13 days (3 -28) . Mortality in ICU patients was higher than in patients hospitalized in the general ward (39.8% versus 31.6%) but this difference did not reach statistical significance (P ¼ 0.240).
Bivariate analysis of risk factors associated with mortality is shown in Table 1 . Patients who died were significantly older than survivors. Among underlying conditions, only previous corticosteroid therapy was significantly more frequent in those who died. As expected, APACHE II score was significantly higher in those who died and mortality rate was greater in those cases presenting as septic shock.
The impact on mortality of adequate antifungal administration is influenced by the timing of catheter withdrawal (Table 2 ). In the total cohort, survival rate was 65.1% (43/66) in those patients with adequate antifungal treatment in the first 48 h and this rate increased to 81.1% (30/37) in those patients that received early adequate antifungal therapy and catheter withdrawal. Similarly, in primary candidaemia the survival rate was 72% (36/50) in those patients with adequate antifungal therapy in the first 48 h and this rate increased to 82.4% (28/34) in those patients that received early adequate antifungal therapy and catheter withdrawal. Garnacho-Montero et al. Table 3 shows the results of the bivariate analysis comparing episodes of primary candidaemia with secondary non-catheterrelated BSI (40 cases). In patients with primary candidaemia, median time from hospital admission to candidaemia presentation was 25.5 days (14 -38) while in secondary candidaemia this time was 20 days (9.5, 29.5) (P ¼ 0.099). There were no significant differences in the species of Candida isolated between patients with primary and secondary non-catheter-related candidaemia except that C. glabrata was less frequently isolated in patients with primary candidaemia (8.1% versus 20.0%; P ¼ 0.042). Of note, C. glabrata was isolated in seven patients with abdominal infection (35%) and in none of the patients with candidaemia with its source in the urinary tract. C. albicans was the most frequently isolated species (77.8%) in candidaemia with its source in the urinary tract. In the case of secondary candidaemia, an abdominal source of infection was associated with the highest mortality rate (62.5%). In contrast, candidaemia originating in the urinary tract exhibited the lowest mortality rate (11.1%) (P¼ 0.03).
The unadjusted and adjusted Cox analyses that determined variables significantly associated with in-hospital mortality in patients with primary and secondary non-catheter-related candidaemia are listed in Table 4 . In primary candidaemia, APACHE II score on the day of candidaemia was independently associated with mortality, whereas early CVC withdrawal was a protective factor and antifungal therapy in the first 48 h did not reach statistical significance, although it exhibited a strong tendency. In patients with secondary non-catheter-related candidaemia, adequate antifungal therapy was a protective factor while early catheter withdrawal was not a risk factor for mortality.
Discussion
Our study discloses that, after adjusting for confounding variables, adequate antifungal therapy of candidaemia and catheter removal within the first 48 h are two strong determinants of survival in patients with candidaemia. The impact on the prognosis of prompt catheter removal persists in patients with primary Candida BSI. However, analysis of the episodes of secondary non-catheter-related candidaemia indicated that the timing of Garnacho-Montero et al.
catheter withdrawal does not influence the outcome and that only early adequate antifungal therapy was statistically associated with greater hospital survival. Severity of illness on the day of BSI has a powerful effect on survival. Recent guidelines for the treatment of candidiasis recommend that the initial management of candidaemia should include removal of all CVCs even in neutropenic patients in whom this strategy may be problematic to perform. 18, 19 There have been no randomized trials in patients with Candida BSI conducted specifically to address the effects of catheter removal versus retention and this design may be considered unethical. Moreover, there are no conclusive data from randomized trials evaluating new antifungal drugs to support this recommendation. 20 -22 Therefore, this recommendation is based on observational studies with conflicting results.
A systematic literature review that included 14 studies did not prove that catheter removal reduces complications or death in candidaemic patients. 23 Analysis of data obtained in a prospective population-based surveillance failed to demonstrate that catheter removal within the first 48 h of the candidaemia episode was an independent predictor of 30 day survival. 4 Two papers have evaluated the effects of early removal of CVCs in adults with candidaemia based on the results of two randomized controlled trials. In the first one, early venous line removal did not improve the time to mycological eradication but was associated with better treatment success and survival in the univariate analysis. However, this benefit was lost in the multivariate analysis. 5 Interestingly, in a second analysis using the same pooled data, catheter removal was associated with a significant benefit with regard to 42 day survival. 24 Similarly, in cancer patients, catheter removal in the first 72 h after candidaemia was an independent predictor of survival. 3 Very recently, a quantitative review of seven randomized trials has identified catheter removal as independently associated with clinical cure and survival, although the timing of line withdrawal was not analysed. 25 These studies included different patient populations and the variables that were taken into account varied notably among them. These factors may explain the different conclusions of these studies. Notably, precocity in the onset of adequate antifungal therapy, a key determinant of survival, was not assessed in these studies.
Of note, a retrospective analysis that evaluated treatment-related factors associated with mortality identified inadequate initial fluconazole dosing and CVC removal .24 h after identification of Candida spp. in the blood culture as independent predictors of mortality. 26 In addition, removal of the CVC and the use of appropriate therapy were independent factors significantly associated with 30 day survival. 27 However, the time to initiation of antifungal administration or delay in catheter removal was not considered in this analysis. In a nationwide study in Iceland, prompt removal of the venous catheter and antifungal therapy were both significantly associated with improved outcome. Nevertheless, the multivariate analysis only identified removal of the central venous line within 48 h of diagnosis as a protective factor against 30 day mortality. 28 On the other hand, diverse studies highlight the importance of early and appropriate empirical therapy in Candida BSIs. Importantly, inappropriate antifungal therapy for Candida spp. BSIs is associated with a significant increase in mortality, length of stay and resource utilization. 6 -10 Nevertheless, other studies concluded that time to initiation of effective antifungal therapy did not influence survival rate. 11 -14 Different factors may explain this discrepancy. Apart from certain methodological differences, it should be mentioned that mortality rate was .55% in studies that did not find an impact on mortality of early antifungal administration. 11, 12 Among more critically ill patients, it is likely that any relation between antifungal initiation and outcome may be masked by the severity of the patient's underlying condition. Importantly, these studies did not evaluate the impact of early catheter removal on the outcome, introducing another confounding factor that may have influenced their results. 6 -13 It is judicious to postulate that early intravenous line removal accelerates the clearance of BSI and reduces the likelihood of a new bloodstream invasion, facilitating the action of the antifungal drug. On the other hand, a recent study did not find a significant association between early appropriate antifungal therapy and outcomes. However, a secondary analysis excluding patients who had not received at least 24 h of adequate antifungal therapy showed a significant mortality benefit. 14 Our results reveal that catheter removal is not useful in secondary non-catheter-related candidaemia in which the venous line is not the origin of candidaemia. However, in this cohort, early adequate antifungal therapy was a strong protective factor. In cancer patients, catheter retention .72 h after onset of candidaemia was an independent predictor of therapy failure exclusively in patients with catheter-related infection, although mortality was unaffected. 29 The distribution of species in primary and secondary non-catheter-related candidaemia episodes also reveals interesting information. C. glabrata was more frequently associated with secondary non-catheter-related candidaemia than with primary episodes. In a recent series of Candida peritonitis, 30 C. glabrata was the second most frequently isolated species after C. albicans. Recent abdominal surgery has also been identified as a risk factor for C. glabrata fungaemia. 31 Moreover, secondary candidaemia originates in a majority of cases from an intra-abdominal source. 12 The poor prognosis of candidaemia secondary to peritonitis and the low mortality of urological episodes are also noteworthy.
We admit several potential limitations of the present study. First, in the cohort of patients with primary candidaemia, primary infections coexisted with catheter-related episodes. It might have been more suitable to analyse them separately. However, in clinical practice it is not always feasible to differentiate primary candidaemia from catheter-related episodes. Hence, this approach is closer to real practice and reduces the probability of type II error. Second, interventions on the focus of candidaemia that may influence the outcome were not evaluated in cases of secondary candidaemia. Third, molecular characterization techniques were not used to confirm the source of the episode. Finally, we did not explore the impact on mortality of source control in patients with secondary non-catheter-related candidaemia. A recent study that enrolled candidaemic patients with septic shock documented the influence on mortality of early antifungal therapy and timely source control. 32 We would also like to emphasize some strengths of our design. We routinely performed antifungal susceptibility testing on all isolates during the study period. Unlike previous studies, this study evaluated the impact on mortality of the two Prognostic factors of Candida spp. bloodstream infections 211 JAC interventions (catheter removal and adequate therapy) that are considered the standard of care in candidaemia. In addition, our evaluation differentiated primary candidaemia, including infections that were probably catheter-related, from secondary non-catheter-related Candida BSI.
In summary, data from this study show that catheter removal within 48 h of the first positive blood culture is life saving and strongly recommended in patients with primary candidaemia, but is not necessary for those with a secondary non-catheter-related candidaemia. These are two different entities whose management may not be the same, at least with respect to venous catheter withdrawal. We reinforce and expand previous findings about the negative impact on survival of delay in effective antifungal therapy. The impact on mortality of adequate antifungal administration is influenced by the timing of catheter removal except in secondary non-catheter-related candidaemia.
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